

# JosÃ© A Paramo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7897874/publications.pdf>

Version: 2024-02-01

42  
papers

1,035  
citations

430442

18  
h-index

433756

31  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1731  
citing authors

#	ARTICLE	IF	CITATIONS
1	CM-352 EFFICACY IN A MOUSE MODEL OF ANTICOAGULANT-ASSOCIATED INTRACRANIAL HAEMORRHAGE. <i>Thrombosis and Haemostasis</i> , 2022, 0, .	1.8	0
2	Lipocalin-2 and Calprotectin Potential Prognosis Biomarkers in Peripheral Arterial Disease. <i>European Journal of Vascular and Endovascular Surgery</i> , 2022, 63, 648-656.	0.8	8
3	Hemostatic Biomarkers and Volumetry Help to Identify High-Risk Abdominal Aortic Aneurysms. <i>Life</i> , 2022, 12, 823.	1.1	0
4	The Role of Circulating Biomarkers in Peripheral Arterial Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3601.	1.8	40
5	Association of SDF1 and MMP12 with Atherosclerosis and Inflammation: Clinical and Experimental Study. <i>Life</i> , 2021, 11, 414.	1.1	9
6	Microvascular thrombosis and clinical implications. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 609-614.	0.1	0
7	Trombosis microvascular y sus implicaciones clínicas. <i>Medicina Clínica</i> , 2021, 156, 609-614.	0.3	4
8	Pulmonary Embolism, Pulmonary Microvascular Thrombosis, or Both in COVID-19?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962093395.	0.7	9
9	Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage. <i>Scientific Reports</i> , 2020, 10, 10329.	1.6	5
10	Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD). <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1729646.	5.5	34
11	Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients with Solid and Hematologic Malignancies. <i>TH Open</i> , 2019, 03, e153-e156.	0.7	0
12	Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients. <i>Journal of Critical Care</i> , 2019, 51, 117-121.	1.0	5
13	Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 428-433.	1.3	2
14	Matrix metalloproteinase-10 deficiency delays atherosclerosis progression and plaque calcification. <i>Atherosclerosis</i> , 2018, 278, 124-134.	0.4	27
15	SP453MATRIX METALLOPROTEINASE-10 AND TISSUE INHIBITOR OF METALLOPROTEINASE-1 (TIMP-1) AS EARLY PREDICTORS OF NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i500-i500.	0.4	1
16	Selective increase of cardiomyocyte derived extracellular vesicles after experimental myocardial infarction and functional effects on the endothelium. <i>Thrombosis Research</i> , 2018, 170, 1-9.	0.8	12
17	CM352 Reduces Brain Damage and Improves Functional Recovery in a Rat Model of Intracerebral Hemorrhage. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	24
18	Arterial spin labeling MRI is able to detect early hemodynamic changes in diabetic nephropathy. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1810-1817.	1.9	73

#	ARTICLE	IF	CITATIONS
19	Reduced high-density lipoprotein cholesterol: A valuable, independent prognostic marker in peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2017, 66, 1527-1533.e1.	0.6	19
20	Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study. <i>European Journal of Haematology</i> , 2016, 97, 128-136.	1.1	2
21	Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/CXCL1 chemokine receptor 4 axis. <i>Hepatology</i> , 2015, 62, 166-178.	3.6	61
22	Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2015, 61, 428-435.	0.6	35
23	Discovery and Safety Profiling of a Potent Preclinical Candidate, (4-[4-[[3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) <sub>2.9</sub> (CM-352), for the Prevention and Treatment of Hemorrhage. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2941-2957.		11
24	Design, Synthesis, and Biological Evaluation of Novel Matrix Metalloproteinase Inhibitors As Potent Antihemorrhagic Agents: From Hit Identification to an Optimized Lead. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2465-2488.	2.9	18
25	Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction. <i>BMC Neurology</i> , 2015, 15, 111.	0.8	11
26	Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. <i>Liver International</i> , 2015, 35, 1590-1596.	1.9	55
27	Rivaroxaban in the Treatment of Venous Thromboembolism and the Prevention of Recurrences. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 297-308.	0.7	6
28	Functional MMP-10 is required for efficient tissue repair after experimental hind limb ischemia. <i>FASEB Journal</i> , 2015, 29, 960-972.	0.2	19
29	Association between Serum Tissue Inhibitor of Matrix Metalloproteinase-1 Levels and Mortality in Patients with Severe Brain Trauma Injury. <i>PLoS ONE</i> , 2014, 9, e94370.	1.1	34
30	The CXCR4/SDF1 Axis Improves Muscle Regeneration Through MMP-10 Activity. <i>Stem Cells and Development</i> , 2014, 23, 1417-1427.	1.1	36
31	Matrix metalloproteinase-10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair. <i>Liver International</i> , 2014, 34, e257-70.	1.9	43
32	Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document". <i>Blood Transfusion</i> , 2013, 11, 585-610.	0.3	108
33	Corrigendum to "Preliminary characterisation of the promoter of the human p22phox gene: Identification of a new polymorphism associated with hypertension" [FEBS Lett. 542 (2003) 27-31]. <i>FEBS Letters</i> , 2010, 584, 4709-4709.	1.3	0
34	Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis. <i>Nephrology</i> , 2010, 15, 178-183.	0.7	31
35	Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. <i>Kidney International</i> , 2010, 78, 1275-1280.	2.6	37
36	Topical Issues in Venous Thromboembolism. <i>Drugs</i> , 2010, 70, 11-18.	4.9	12

#	ARTICLE	IF	CITATIONS
37	Integrating soluble biomarkers and imaging technologies in the identification of vulnerable atherosclerotic patients. <i>Biomarker Insights</i> , 2007, 1, 165-73.	1.0	3
38	Integrating Soluble Biomarkers and Imaging Technologies in the Identification of Vulnerable Atherosclerotic Patients. <i>Biomarker Insights</i> , 2006, 1, 117727190600100.	1.0	1
39	Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer. <i>Clinical and Translational Oncology</i> , 2005, 7, 150-155.	1.2	15
40	Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. <i>Atherosclerosis</i> , 2003, 170, 269-276.	0.4	98
41	Vitamins C and E downregulate vascular VEGF and VEGFR-2 expression in apolipoprotein-E-deficient mice. <i>Atherosclerosis</i> , 2003, 171, 67-73.	0.4	64
42	PURIFICATION AND CHARACTERIZATION OF A VARIANT OF HUMAN PROTHROMBIN: PROTHROMBIN SEGOVIA. <i>Thrombosis Research</i> , 1997, 85, 465-477.	0.8	7